LAS VEGAS, NV, April 18 /PRNewswire-FirstCall/ - Neuroscience Therapy Corp. announced today that it has gained hold of the exclusive rights to the North American market to distribute its leading product P-Stim. It now holds rights in North, South and Central America and plans to thrive in these multi-billion dollar markets.
Acquiring the rights to distribute P-Stim in North America should greatly enhance the Company's revenue stream. According to the National Institute of Health, pain is the most common reason for medical appointments, nearly 40 million visits annually, and costs the U.S. over $10 billion each year in health care and lost productivity.
Neuroscience plans to take advantage of the huge U.S. market with P-Stim, its leading product, which has been proven effective in Europe and has no known side effects, unlike many pharmaceutical pain relievers.
Neuroscience President, Dr. Randolph A. Turpin said, "Now that we have distribution rights in North, South and Central America, we have the opportunity to greatly increase our revenues and to significantly grow our business."
About Neuroscience Therapy Corporation:
Neuroscience Therapy Corporation's operations are located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complimentary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com .
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Contact: Neuroscience Therapy Corporation Raymond Johnson 1-866-639-3900
Neuroscience Therapy CorporationCONTACT: Neuroscience Therapy Corporation, Raymond Johnson, 1-866-639-3900
